Business Impacts of Natural Disasters, Infectious Diseases, War, Terrorism and Other Events
First written in FY2016. 8 of 18 entries say "Mitigated", first in FY2021-Q1. Latest entry: FY2024.
The whole theme swung hardest in 2020: 67 of 114 companies on the "Worse" side.
- FY2024MitigatedAnnual report
「The number of catheter-treatment cases worldwide had declined following the recent outbreak of COVID-19, but is now trending toward recovery. The Group’s manufacturing plants are located in Thailand, Vietnam and the Philippines, and these plants have had no major operational issues caused by COVID-19, with no problems arising in product supplies.」
The Group explained that the number of cases is trending toward recovery and that the manufacturing plants in Thailand, Vietnam and the Philippines have continued supplying products without major operational issues caused by the infectious disease. - FY2024-Q2MitigatedAnnual report
「Medical operations saw an increase in sales as the impact of COVID-19 largely subsided and markets recovered and expanded, due to the effect of stronger foreign currencies, increased market needs mainly overseas, and concentrated orders from distributors and other customers.」
The Group explained that the impact of COVID-19 had largely subsided and markets had recovered and expanded, reaffirming the reduction in the market-contraction risk associated with the infectious disease. - FY2024-Q1MitigatedAnnual report
「Medical operations saw an increase in sales due to market recovery and expansion as the impact of COVID-19 subsided, the effect of stronger foreign currencies, increased market needs mainly overseas, and concentrated orders from distributors and other customers.」
The Group indicated that markets were recovering and expanding as the impact of COVID-19 subsided, reducing the market-contraction risk associated with the infectious disease compared with the previous fiscal year. - FY2023MitigatedAnnual report
「The number of catheter-treatment cases worldwide had declined following the recent outbreak of COVID-19, but is now trending toward recovery. The Group’s manufacturing plants are located in Thailand, Vietnam and the Philippines, and these plants have had no major operational issues caused by COVID-19, with no problems arising in product supplies.」
The number of cases worldwide is trending toward recovery, and the manufacturing plants in Thailand, Vietnam and the Philippines have continued supplying products without major operational issues caused by the infectious disease. - FY2023-Q1MitigatedAnnual report
「Net income attributable to owners of the parent was ¥4,049 million, up 21.5% year on year. This reflected the recording of ¥305 million in disaster insurance proceeds related to the typhoon damage at the Cebu factory, despite a decline of ¥615 million in the gain on step acquisitions.」
Regarding the damage to the Cebu Plant caused by Typhoon Rai, the Group recognised ¥305 million in disaster insurance proceeds, which partially compensated for the losses caused by the natural disaster. - FY2022MitigatedAnnual report
「The number of catheter-treatment cases worldwide had declined following the outbreak of COVID-19, but has gradually been recovering globally as the spread of COVID-19 has subsided. The Group’s manufacturing plants are located in Thailand, Vietnam and the Philippines. Although these regions have been affected by COVID-19, there are currently no major issues with plant operations, and no problems have arisen with product supplies.」
The number of cases worldwide is gradually recovering, and the manufacturing plants in Thailand, Vietnam and the Philippines have continued supplying products without major operational issues. - FY2022-Q3MaterialisedAnnual report
「Although the worsening situation involving Russia and Ukraine has had an impact, the impact was minor compared with the year-earlier period.」
The Group stated that, in addition to the general war risk previously disclosed, an impact from the worsening situation involving Russia and Ukraine had materialised. However, it considered the impact minor compared with the year-earlier period. - FY2022-Q2MaterialisedAnnual report
「On 16 December 2021, Typhoon Rai struck the Philippines, damaging the Group’s consolidated subsidiary TOYOFLEX CEBU CORPORATION, hereinafter the Cebu Plant, mainly in its device business. All operations, including product shipments, were temporarily suspended as a result, but operations have been gradually resuming since mid-January. During the cumulative second-quarter period, part of the damage caused by the typhoon was recognised as an extraordinary loss.」
The natural disaster risk materialised in the form of damage to the Cebu Plant from the typhoon, a suspension of operations, and recognition of a disaster loss of ¥249 million. However, the Group stated that the loss could be covered by insurance proceeds and would not have a material impact on full-year results. - FY2022-Q1MitigatedAnnual report
「Overseas sales increased substantially to ¥18.120 billion, up 25.8% year on year, due to the recovery in the contraction of the market caused by COVID-19, increased market needs, and the completion of multiple acquisitions.」
The Group explained that the impact of the COVID-19-related market contraction was trending toward recovery year on year, and that overseas sales increased. However, the impact of the decline in the number of cases due to the infectious disease remained. - FY2021WorsenedAnnual report
「However, COVID-19 has recently begun spreading rapidly again, including due to the Delta variant, and the trend in the number of cases remains unstable.」
Although the number of cases was beginning to recover, the Group newly identified the renewed spread of infections due to the Delta variant and the instability in the number of cases. - FY2021-Q3WorsenedAnnual report
「Based on the five-year medium-term management plan “ASAHI Road to 1000: Aiming to become a strong global niche No. 1 through Only One technology,” the Group is pursuing “strategic development of global markets and expansion of affected areas and treatment fields” as it builds a business portfolio aimed at achieving ¥100 billion in consolidated net sales. Through this initiative, it is consolidating its basic strategies to date and strengthening the earnings base of its existing businesses. By continuing to invest in growth toward the future, it aims to create new businesses in global niche markets, strengthen its presence in those markets and further enhance corporate value. To support this growth strategy, the Group is developing a business foundation consisting of an R&D and production structure optimized for global expansion and a management foundation for sustainable growth. Under the plan, the Group aims to achieve consolidated net sales of ¥80 billion in the fiscal year ending June 2023 as a milestone toward ¥100 billion, with an operating margin target of approximately 25% at that point.」
Regarding COVID-19, the Group indicated that the recovery in the number of cases had stalled during the third quarter after the decline passed its peak, and that uncertainty about the impact continues. - FY2021-Q2RestatedAnnual report
「The decline has now passed its peak, and the number of cases is also trending toward recovery globally. However, the outlook remains uncertain.」
The Group reiterated that, although the decline in the number of cases due to COVID-19 has passed its peak and is trending toward recovery, the outlook remains uncertain. - FY2021-Q1MitigatedAnnual report
「The decline has now passed its peak, and the number of cases is also trending toward recovery globally. However, the outlook remains uncertain.」
Regarding the global decline in the number of cases due to COVID-19, the Group added that the decline had passed its peak and was trending toward recovery. At the same time, uncertainty about the outlook continues. - FY2020WorsenedAnnual report
「The Group sells its products globally, but the spread of COVID-19 in countries around the world has temporarily reduced the number of cases involving endovascular catheter treatment, as only highly urgent cases have been performed. As a result, the Group’s sales have been trending downward.」
The impact of COVID-19 expanded from an explanation focused mainly on the Chinese market to countries worldwide and a global scale, with the decline in the number of cases and sales confirmed over the full fiscal year. - FY2020-Q3MaterialisedAnnual report
「The Group sells its products globally, but the spread of COVID-19 in countries around the world has temporarily reduced the number of cases involving endovascular catheter treatment, as only highly urgent cases have been performed. As a result, the Group’s sales have been trending downward.」
The infectious disease risk previously disclosed as a possibility has materialised with the spread of COVID-19, resulting in a decline in the number of cases and a downward trend in sales. - FY2019RestatedAnnual report
「The Group sells its products globally. If a natural disaster, illness, infectious disease, war, terrorism or other event occurs in a region where the Group operates, it may affect the Group’s business results.」
The Group continues to identify external shocks associated with its global operations, including natural disasters, infectious diseases, war and terrorism, as risks. - FY2017RestatedAnnual report
「If a natural disaster, illness, infectious disease, war, terrorism or other event occurs in a region where the Group operates, it may affect the Group’s business results.」
The Group continues to identify external shocks associated with its global operations, including natural disasters, infectious diseases, war and terrorism, as risks. - FY2016First statedAnnual report
「If a natural disaster, illness, infectious disease, war, terrorism or other event occurs in a region where the Group operates, it may affect the Group’s business results.」
The Group identifies external shocks associated with its global operations as a risk.